Relief Therapeutics Holding AG
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.56
- Today's High:
- $6.56
- Open Price:
- $6.56
- 52W Low:
- $4.67
- 52W High:
- $6.84
- Prev. Close:
- $6.8
- Volume:
- 129
Company Statistics
- Market Cap.:
- $175.28 million
- Book Value:
- 7.6
- Revenue TTM:
- $6.56 million
- Operating Margin TTM:
- -596.18%
- Gross Profit TTM:
- $2.57 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -12.17%
- Return on Equity TTM:
- -32.57%
Company Profile
Relief Therapeutics Holding AG had its IPO on under the ticker symbol RLFTD.
The company operates in the Healthcare sector and Biotechnology industry. Relief Therapeutics Holding AG has a staff strength of 10 employees.
Stock update
Shares of Relief Therapeutics Holding AG opened at $6.56 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.56 - $6.56, and closed at $6.56.
This is a -3.53% slip from the previous day's closing price.
A total volume of 129 shares were traded at the close of the day’s session.
In the last one week, shares of Relief Therapeutics Holding AG have slipped by -3.53%.
Relief Therapeutics Holding AG's Key Ratios
Relief Therapeutics Holding AG has a market cap of $175.28 million, indicating a price to book ratio of 0.7602 and a price to sales ratio of 26.708.
In the last 12-months Relief Therapeutics Holding AG’s revenue was $6.56 million with a gross profit of $2.57 million and an EBITDA of $0. The EBITDA ratio measures Relief Therapeutics Holding AG's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Relief Therapeutics Holding AG’s operating margin was -596.18% while its return on assets stood at -12.17% with a return of equity of -32.57%.
In Q2, Relief Therapeutics Holding AG’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Relief Therapeutics Holding AG’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Relief Therapeutics Holding AG’s profitability.
Relief Therapeutics Holding AG stock is trading at a EV to sales ratio of 15.6547 and a EV to EBITDA ratio of -2.3359. Its price to sales ratio in the trailing 12-months stood at 26.708.
Relief Therapeutics Holding AG stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $221.83 million
- Total Liabilities
- $12.48 million
- Operating Cash Flow
- $-2382000.00
- Capital Expenditure
- $12500
- Dividend Payout Ratio
- 0%
Relief Therapeutics Holding AG ended 2024 with $221.83 million in total assets and $0 in total liabilities. Its intangible assets were valued at $221.83 million while shareholder equity stood at $161.42 million.
Relief Therapeutics Holding AG ended 2024 with $0 in deferred long-term liabilities, $12.48 million in other current liabilities, 44163000.00 in common stock, $-96251000.00 in retained earnings and $7.02 million in goodwill. Its cash balance stood at $29.87 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $385000.00.
Relief Therapeutics Holding AG’s total current assets stands at $34.99 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $3.52 million compared to accounts payable of $1.55 million and inventory worth $243000.00.
In 2024, Relief Therapeutics Holding AG's operating cash flow was $-2382000.00 while its capital expenditure stood at $12500.
Comparatively, Relief Therapeutics Holding AG paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.56
- 52-Week High
- $6.84
- 52-Week Low
- $4.67
- Analyst Target Price
- $
Relief Therapeutics Holding AG stock is currently trading at $6.56 per share. It touched a 52-week high of $6.84 and a 52-week low of $6.84. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $6.17 and 200-day moving average was $7.25 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Relief Therapeutics Holding AG
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.